Clinical Trials for Non-Small Cell Lung Cancer

A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell Lung Cancer (NSCLC) Following Chemoimmunotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets patients with Stage IV NSCLC who have progressed after first-line chemoimmunotherapy and explores the combination of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, with docetaxel.

ClinicalTrials.gov ID: NCT06841055

A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic EGFR-mutated NSCLC (exon 19 deletion, L858R, and/or T790M) and MET overexpression/amplification who have progressed on osimertinib, randomizing them to savolitinib (a selective MET inhibitor) plus osimertinib versus platinum-based doublet chemotherapy with pemetrexed. Eligible patients must have ECOG 0-1 and no prior MET inhibitor use or uncontrolled comorbidities.

ClinicalTrials.gov ID: NCT05261399

A Phase 2 Study of Defactinib and Avutometinib, in Combination With Nivolumab for Patients With Anti-PD1 Refractory LKB1-Mutant Advanced Lung Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial is enrolling adults with advanced, LKB1-mutant, anti-PD1-refractory lung adenocarcinoma (including KRAS-mutant subset), testing the combination of oral defactinib (FAK/Pyk2 inhibitor), oral avutometinib (dual RAF/MEK inhibitor), and intravenous nivolumab. Eligible patients must have progressed on prior anti-PD1 therapy and first line chemotherapy, and have ECOG 0-1.

ClinicalTrials.gov ID: NCT06495125

A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced non-squamous NSCLC who have progressed after anti-PD(L)1 therapy or, for EGFR-mutant patients, after EGFR-targeted therapy, to receive tiragolumab (a TIGIT inhibitor), atezolizumab, and bevacizumab. Key eligibility includes ECOG 0-2, no known driver mutations (except EGFR-mutant cohort), and no untreated/symptomatic CNS metastases.

ClinicalTrials.gov ID: NCT04958811

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with previously untreated advanced or metastatic non-squamous NSCLC, high PD-L1 expression (TPS ≥50%), and no EGFR, ALK, or ROS1 alterations, randomizing them to pembrolizumab alone or in combination with datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate delivering a topoisomerase I inhibitor. Prior immune checkpoint inhibitor or TROP2-targeted therapy is not allowed.

ClinicalTrials.gov ID: NCT05215340

A Phase 2, Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring a deleterious SMARCA4 mutation or loss of SMARCA4 protein expression, specifically focusing on esophageal cancer and NSCLC for efficacy evaluation. Patients receive PRT3789, a selective SMARCA2 degrader exploiting synthetic lethality in SMARCA4-deficient tumors, in combination with pembrolizumab.

ClinicalTrials.gov ID: NCT06682806

A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with stage IV metastatic NSCLC and good performance status to evaluate several immunotherapy-based combinations—including domvanalimab (TIGIT inhibitor), quemliclustat (CD73 inhibitor), and zimberelimab (anti-PD-1)—with or without platinum-based chemotherapy or docetaxel. Eligible patients should have measurable disease and no significant immunosuppression or active autoimmune disorders.

ClinicalTrials.gov ID: NCT05676931

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with untreated stage 4 non-small cell lung cancer (both squamous and non-squamous, without actionable oncogenic drivers) who receive EIK1001—a dual TLR7/8 agonist that activates dendritic cells—combined with pembrolizumab and standard platinum-doublet chemotherapy according to histology.

ClinicalTrials.gov ID: NCT06246110

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with untreated metastatic non-squamous NSCLC lacking actionable driver mutations, randomizing them to receive either livmoniplimab (anti-GARP/TGF-β1) plus budigalimab (anti-PD-1) with platinum-based chemotherapy, or pembrolizumab (anti-PD-1) with chemotherapy. The investigational regimen aims to enhance anti-tumor immune activity by targeting both PD-1 and Treg-mediated immunosuppression.

ClinicalTrials.gov ID: NCT06236438

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls treatment-naïve patients with stage IV non-squamous NSCLC (ECOG 0–1, no EGFR or other driver mutations) and randomizes them to one of two volrustomig priming regimens (a novel PD-1/CTLA-4 bispecific antibody) in combination with carboplatin and pemetrexed. Patients with stable, asymptomatic brain metastases may also be eligible.

ClinicalTrials.gov ID: NCT06448754